{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:22:39Z","timestamp":1790194959447,"version":"4.1.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1097\/jcp.0b013e318272cdd8","type":"journal-article","created":{"date-parts":[[2012,11,6]],"date-time":"2012-11-06T10:17:20Z","timestamp":1352197040000},"page":"824-827","source":"Crossref","is-referenced-by-count":30,"title":["Drugs Associated With Restless Legs Syndrome"],"prefix":"10.1097","volume":"32","author":[{"given":"Santiago","family":"Perez-Lloret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Ver\u00f3nica","family":"Rey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle","family":"Bondon-Guitton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"and Jean-Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210128","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2796.2009.02159.x","article-title":"Restless legs syndrome.","volume":"266","author":"Ekbom","year":"2009","journal-title":"J Intern Med"},{"key":"R2-16-20210128","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S1474-4422(05)70139-3","article-title":"The restless legs syndrome.","volume":"4","author":"Trenkwalder","year":"2005","journal-title":"Lancet Neurol"},{"key":"R3-16-20210128","doi-asserted-by":"crossref","first-page":"79","DOI":"10.5664\/jcsm.27716","article-title":"Pharmacologically inducedexacerbated restless legs syndrome, periodic limb movements of sleep, and REM behavior disorderREM sleep without atonia: literature review, qualitative scoring, and comparative analysis.","volume":"6","author":"Hoque","year":"2010","journal-title":"J Clin Sleep Med"},{"key":"R4-16-20210128","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jbspin.2006.09.002","article-title":". Pharmacovigilance for evaluating adverse drug reactions: value, organization, and methods.","volume":"73","author":"Montastruc","year":"2006","journal-title":"Joint Bone Spine"},{"key":"R5-16-20210128","first-page":"111","article-title":". Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France.","volume":"40","author":"Begaud","year":"1985","journal-title":"Therapie"},{"key":"R6-16-20210128","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","article-title":"Adverse drug reactions: definitions, diagnosis, and management.","volume":"356","author":"Edwards","year":"2000","journal-title":"Lancet"},{"key":"R7-16-20210128","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S1389-9457(03)00010-8","article-title":". Restless legs syndrome: diagnostic criteria, special considerations, and epidemiology. A report from the restless legs syndrome diagnosis and epidemiology workshop at the National Institutes of Health.","volume":"4","author":"Allen","year":"2003","journal-title":"Sleep Med"},{"key":"R8-16-20210128","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2165\/00002018-200225060-00010","article-title":"Use of measures of disproportionality in pharmacovigilance: three Dutch examples.","volume":"25","author":"Egberts","year":"2002","journal-title":"Drug Saf"},{"key":"R9-16-20210128","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.1997.00615.x","article-title":". Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a casenon-case study in the French pharmacovigilance system database.","volume":"44","author":"Moore","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"R10-16-20210128","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1046\/j.1365-2125.2003.01968.x","article-title":"Application of data mining techniques in pharmacovigilance.","volume":"57","author":"Wilson","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"R11-16-20210128","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/pds.1248","article-title":"The nature of the scientific evidence leading to drug withdrawals for pharmacovigilance reasons in France.","volume":"15","author":"Olivier","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R12-16-20210128","doi-asserted-by":"crossref","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","article-title":"Under-reporting of adverse drug reactions: a systematic review.","volume":"29","author":"Hazell","year":"2006","journal-title":"Drug Saf"},{"key":"R13-16-20210128","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1001\/jama.288.13.1588","article-title":". Rates of spontaneous reporting of adverse drug reactions in France.","volume":"288","author":"Begaud","year":"2002","journal-title":"JAMA"},{"key":"R14-16-20210128","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1111\/j.1365-2125.2009.03472.x","article-title":". Reporting rate of adverse drug reactions to the French pharmacovigilance system with three step 2 analgesic drugs: dextropropoxyphene, tramadol and codeine (in combination with paracetamol).","volume":"68","author":"Tavassoli","year":"2009","journal-title":"Br J Clin Pharmacol"},{"key":"R15-16-20210128","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1111\/j.1365-2125.2009.03596.x","article-title":". Drugs and dilated cardiomyopathies: a casenoncase study in the French PharmacoVigilance Database.","volume":"69","author":"Montastruc","year":"2010","journal-title":"Br J Clin Pharmacol"},{"key":"R17-16-20210128","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1176\/ajp.143.11.1490b","article-title":"Nocturnal cataclysms with myoclonus: a new side effect of clomipramine.","volume":"143","author":"Myers","year":"1986","journal-title":"Am J Psychiatry"},{"key":"R18-16-20210128","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1192\/bjp.155.3.415","article-title":". Mianserin-induced restless legs syndrome.","volume":"155","author":"Paik","year":"1989","journal-title":"Br J Psychiatry"},{"key":"R19-16-20210128","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.4088\/JCP.v63n1214a","article-title":". Restless legs syndrome induced by mirtazapine.","volume":"63","author":"Agargun","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"R20-16-20210128","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.jpsychires.2008.02.006","article-title":". Restless legs syndrome as side effect of second generation antidepressants.","volume":"43","author":"Rottach","year":"2008","journal-title":"J Psychiatr Res"},{"key":"R21-16-20210128","first-page":"33","article-title":". Nocturnal eatingdrinking syndrome and neuroleptic-induced restless legs syndrome.","volume":"14","author":"Horiguchi","year":"1999","journal-title":"Int Clin Psychopharmacol"},{"key":"R22-16-20210128","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/00004714-199910000-00017","article-title":"Periodic leg movements in sleep and restless legs syndrome probably caused by olanzapine.","volume":"19","author":"Kraus","year":"1999","journal-title":"J Clin Psychopharmacol"},{"key":"R23-16-20210128","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1055\/s-2002-31514","article-title":"Restless legs syndrome probably induced by risperidone treatment.","volume":"35","author":"Wetter","year":"2002","journal-title":"Pharmacopsychiatry"},{"key":"R24-16-20210128","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.sleep.2006.05.011","article-title":"Restless legs syndrome augmentation associated with tramadol.","volume":"7","author":"Earley","year":"2006","journal-title":"Sleep Med"},{"key":"R25-16-20210128","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mds.21342","article-title":". Augmentation of restless legs syndrome with long-term tramadol treatment.","volume":"22","author":"Vetrugno","year":"2007","journal-title":"Mov Disord"},{"key":"R26-16-20210128","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1002\/hup.965","article-title":". Factors potentiating the risk of mirtazapine-associated restless legs syndrome.","volume":"23","author":"Kim","year":"2008","journal-title":"Hum Psychopharmacol"},{"key":"R27-16-20210128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2515\/therapie:2006011","article-title":". Drugs, Parkinsons disease and parkinsonian syndrome: recent advances in pharmacovigilance.","volume":"61","author":"Montastruc","year":"2006","journal-title":"Therapie"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0b013e318272cdd8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:00:31Z","timestamp":1620957631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00004714-201212000-00016"}},"subtitle":["A Case\/Noncase Study in the French Pharmacovigilance Database"],"short-title":[],"issued":{"date-parts":[[2012,12]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0b013e318272cdd8","relation":{},"ISSN":["0271-0749"],"issn-type":[{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2012,12]]}}}